Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge
Gastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembro...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2019.02.008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Gastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembrolizumab, for instance, has been approved in the USA in 2017, with the indication of advanced gastric and esophageal programmed death-ligand 1 (PD-L1)-positive tumors, as well as for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) solid tumors.^1,2^
Signals of outstanding efficacy were particularly observed in biomarker selected populations.^3^ Hence, there is an urgent need to identify precise predictive biomarkers for optimal patient selection and to establish more effective treatment timings.
The present review summarizes the current clinical evidence supporting treatment with ICIs in upper GI tumors. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |